TrialDiabetologia2019

Randomised, phase 1, dose-finding study of MEDI4166, a PCSK9 antibody and GLP-1 analogue fusion molecule, in overweight or obese patients with type 2 diabetes mellitus.

Meena Jain et al.PubMed ↗Publisher ↗

No numbers read from the abstract.